AU4990599A - Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization - Google Patents

Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Info

Publication number
AU4990599A
AU4990599A AU49905/99A AU4990599A AU4990599A AU 4990599 A AU4990599 A AU 4990599A AU 49905/99 A AU49905/99 A AU 49905/99A AU 4990599 A AU4990599 A AU 4990599A AU 4990599 A AU4990599 A AU 4990599A
Authority
AU
Australia
Prior art keywords
upregulation
agents
nitric oxide
endothelial cell
type iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49905/99A
Inventor
James K. Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/115,387 external-priority patent/US6423751B1/en
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU4990599A publication Critical patent/AU4990599A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU49905/99A 1998-07-14 1999-07-14 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization Abandoned AU4990599A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/115,387 US6423751B1 (en) 1998-07-14 1998-07-14 Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US09115387 1998-07-14
US27322499A 1999-03-19 1999-03-19
US09273224 1999-03-19
PCT/US1999/015827 WO2000003746A2 (en) 1998-07-14 1999-07-14 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Publications (1)

Publication Number Publication Date
AU4990599A true AU4990599A (en) 2000-02-07

Family

ID=26813141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49905/99A Abandoned AU4990599A (en) 1998-07-14 1999-07-14 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Country Status (2)

Country Link
AU (1) AU4990599A (en)
WO (1) WO2000003746A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6239172B1 (en) 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
EP1370210A4 (en) * 2001-02-07 2004-08-18 Mclean Hospital Corp Cholesterol-lowering agents as treatment for psychological and cognitive disorders
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
PE20020856A1 (en) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-TETRAHYDRONAFTIL ACILATED AMINES
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
WO2003047591A1 (en) * 2001-11-30 2003-06-12 Asahi Kasei Pharma Corporation Remedies for primary pulmonary hypertension
FR2833839A1 (en) * 2001-12-21 2003-06-27 Rytek Use of pulmonary epithelial cell myosin contraction inhibitors for the treatment or prevention of respiratory disorders such as asthma, allergies, and chronic obstructive lung diseases.
FR2833840B1 (en) * 2001-12-21 2010-06-18 Rytek METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY PATHOLOGIES
FR2837103B1 (en) * 2002-03-15 2004-07-09 Rytek COMPOSITIONS FOR THE TREATMENT OF DIGESTIVE FUNCTIONAL CONDITIONS
FR2844201A1 (en) * 2002-09-06 2004-03-12 Rytek Use of compound that controls the opening of intestinal epithelium tight junctions for prevention and cure of hyperalgesic intestinal disorders
EP1485074A2 (en) 2002-03-15 2004-12-15 Rytek Compositions for treating digestive functional pathologies
HUE027779T2 (en) 2002-05-09 2016-11-28 Brigham & Womens Hospital Inc 1L1RL-1 as a cardiovascular disease marker
US7105513B2 (en) 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
CA2400254A1 (en) * 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
US7132536B2 (en) 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
PT1708690T (en) 2003-11-17 2016-09-19 Biomarin Pharm Inc Treatment of phenylketonuria with bh4
EP1729761A4 (en) * 2004-03-05 2008-09-03 Eisai Co Ltd Cadasil treatment with cholinesterase inhibitors
FR2879100B1 (en) 2004-12-09 2007-07-06 Lionel Bueno COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE PATHOLOGIES AND RETINA
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
BRPI0912337A2 (en) * 2008-05-12 2019-09-24 Amnestix Inc compound method for improving patient memory, and method for treating conditions
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (en) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 How to treat anxiety disorders, headache disorders and eating disorders with psilocybin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583287D1 (en) * 1984-12-27 1991-07-25 Asahi Chemical Ind SUBSTITUTED ISOCHINOLINSULFONYL COMPOUNDS.
JPS6287581A (en) * 1985-10-11 1987-04-22 Hokuriku Seiyaku Co Ltd Naphthalenesulfonamide derivative
JP2528451B2 (en) * 1986-07-09 1996-08-28 北陸製薬株式会社 Naphthalene sulfonamide derivative
WO1991006293A2 (en) * 1989-11-01 1991-05-16 University Of Vermont And State Agricultural College Composition containing 2,3-butanedione monoxime and method for reversibly arresting muscle activity
JPH0725786A (en) * 1990-05-16 1995-01-27 Univ Rockefeller Medical treatment of amyloidosis accompanying alzheimer desease
JP2893029B2 (en) * 1992-08-10 1999-05-17 旭化成工業株式会社 Cardioprotectant
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
WO1995014465A2 (en) * 1993-11-22 1995-06-01 The Johns Hopkins University Methods for amelioration of immunodeficiency virus induced neurodegeneration by covering nitric oxide or superoxide concentration
US5830910A (en) * 1995-10-23 1998-11-03 University Of Kentucky Research Foundation Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
AU5977598A (en) * 1997-02-07 1998-08-26 Synapse Pharmaceutical International, Inc. Pharmaceutical composition for treatment of synaptic dysfunction comprising an oxime
AU8173098A (en) * 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US6180597B1 (en) * 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors

Also Published As

Publication number Publication date
WO2000003746A2 (en) 2000-01-27
WO2000003746A3 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
AU4990599A (en) Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AU2002211378A1 (en) High performance lithium or lithium ion cell
AU2001253077A1 (en) Electrochemical cell and assembly for same
AU2002246664A1 (en) Lipid-based nitric oxide donors
NO20006044L (en) Nitric oxide synthase inhibitors
ZA98179B (en) Nitric oxide synthase inhibitors.
GB2372627B (en) Fuel cell and fuel cell stack
IS5053A (en) 6-Phenylpyridyl-2-amine derivatives useful as nitric oxide synthase inhibitors
AU2001292539A1 (en) Fuel cell assembly and method for making the same
AU6261798A (en) Flow cell selex
AU1704200A (en) Charge reduction in electrospray mass spectrometry
AU2001245749A1 (en) Fuel cell stack assembly
AU2001271241A1 (en) Uninterruptible power supplies employing fuel cells
AU3850199A (en) Nonaqueous secondary cell and method for controlling the same
WO2000077652A3 (en) Sequence partitioning in cell structures
AU2002226882A1 (en) Improved cell carrier grids
AU5170900A (en) Cell proliferation inhibitors
DE69907918D1 (en) Solar cell COMPONENT
AU2003211785A1 (en) Solid oxide type fuel cell and separator
EP1175246A4 (en) UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
AUPQ584800A0 (en) An electrical reduction cell
AU9508998A (en) Methods and compositions for binding hematopoietic stem cells
AU2003224637A1 (en) High performance fuel cells
GB0006125D0 (en) Fuel cells
AU9732098A (en) Hematopoietic stem cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase